Revenue Estimates Analysis: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)


Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) reported its last earnings on Aug 09 BMO (BMO = before market open, AMC= after market close). The company will report its next earnings on Nov 7 – Nov 11 (Est.). The company reported the earnings of $-0.47/Share in the last quarter where the estimated EPS by analysts was $-0.53/share. The difference between the expected and actual EPS was $0.06/share, which represents an Earnings surprise of 11.3%.

Many analysts are providing their Estimated Earnings analysis for Ionis Pharmaceuticals, Inc. and for the current quarter 12 analysts have projected that the stock could give an Average Earnings estimate of $0.09/share. These analysts have also projected a Low Estimate of $-0.02/share and a High Estimate of $0.36/share.

In case of Revenue Estimates, 12 analysts have provided their consensus Average Revenue Estimates for Ionis Pharmaceuticals, Inc. as 110.59 Million. According to these analysts, the Low Revenue Estimate for Ionis Pharmaceuticals, Inc. is 73.8 Million and the High Revenue Estimate is 145 Million. The company had Year Ago Sales of 49.12 Million.

These analysts also forecasted Growth Estimates for the Current Quarter for IONS to be 130%. They are projecting Next Quarter growth of 78%. For the next 5 years, Ionis Pharmaceuticals, Inc. is expecting Growth of 41% per annum, whereas in the past 5 years the growth was 0% per annum.

Some buy side analysts are also providing their Analysis on Ionis Pharmaceuticals, Inc., where 1 analysts have rated the stock as Strong buy, 3 analysts have given a Buy signal, 8 said it’s a HOLD, 0 reported it as Underperform and 1 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

When it comes to the Analysis of a Stock, Price Target plays a vital role. 9 Analysts reported that the Price Target for Ionis Pharmaceuticals, Inc. might touch $64 high while the Average Price Target and Low price Target is $40.22 and $17 respectively.

To analyze a stock, one should look for Upgrades and Downgrades of a stock. Ionis Pharmaceuticals, Inc. got Initiated on 3-Aug-16 where investment firm Morgan Stanley Initiated the stock to Equal-Weight.

Ionis Pharmaceuticals, Inc. closed its last trading session at $29.69 with the loss of -0.13%. The Market Capitalization of the company stands at 3.58 Billion. The Company has 52-week high of $65.34 and 52-week low of $19.59. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -13.01% where SMA50 and SMA200 are 0.83% and -13.28% respectively. The Company Touched its 52-Week High on Nov 11, 2015 and 52-Week Low on May 27, 2016.

The Relative Volume of the company is 2.21 and Average Volume (3 months) is 2.61 million. Ionis Pharmaceuticals, Inc. P/E (price to earnings) ratio is 0 and Forward P/E ratio of 0.

The company shows its Return on Assets (ROA) value of -25.1%. The Return on Equity (ROE) value stands at -126.9%. While it’s Return on Investment (ROI) value is -11.3%.

While looking at the Stock’s Performance, Ionis Pharmaceuticals, Inc. currently shows a Weekly Performance of -6.29%, where Monthly Performance is -21.44%, Quarterly performance is 24.84%, 6 Months performance is -22.81% and yearly performance percentage is 0%. Year to Date performance value (YTD perf) value is -40.92%. The Stock currently has a Weekly Volatility of 4.57% and Monthly Volatility of 4.35%.